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Abstract
Background: The objective was to explore the relationship between left ventricular ejection
fraction (LVEF) assessed during hospitalization for acute myocardial infarction (MI) and later health-
related quality of life (HRQoL).
Methods: We used multivariable linear regression to assess the relationship between LVEF and
HRQoL in 256 MI patients who responded to the Kansas City Cardiomyopathy Questionnaire
(KCCQ), the EQ-5D Index, and the EuroQol Visual Analogue Scale (EQ-VAS) 2.5 years after the
index MI.
Results: 167 patients had normal LVEF (>50%), 56 intermediate (40%–50%), and 33 reduced
(<40%). The mean (SD) KCCQ clinical summary scores were 85 (18), 75 (22), and 68 (21) (p
<0.001) in the three groups, respectively. The corresponding EQ-5D Index scores were 0.83
(0.18), 0.72 (0.27), and 0.76 (0.14) (p = 0.005) and EQ-VAS scores were 72 (18), 65 (21), and 57
(20) (p  = 0.001). In multivariable linear regression analysis age ≥ 70 years, known chronic
obstructive pulmonary disease (COPD), subsequent MI, intermediate LVEF, and reduced LVEF
were independent determinants for reduced KCCQ clinical summary score. Female sex,
medication for angina pectoris at discharge, and intermediate LVEF were independent determinants
for reduced EQ-5D Index score. Age ≥ 70 years, COPD, and reduced LVEF were associated with
reduced EQ-VAS score.
Conclusion: LVEF measured during hospitalization for MI was a determinant for HRQoL 2.5 years
later.
Background
Left ventricular ejection fraction (LVEF) is the single most
used non-invasive measure of cardiac function in clinical
practice and is an important prognostic factor for survival
after myocardial infarction (MI), in stable coronary artery
disease (CAD), and in heart failure [1-3]. Health-related
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quality of life (HRQoL) has also been identified as a pre-
dictor of survival in patients with CAD and heart failure
[4-7].
However, the relationship between LVEF and HRQoL has
not been settled and whether LVEF can predict HRQoL is
still controversial. Some studies have observed an associ-
ation [8-11] while others have not [12-17]. Most of these
studies reported on highly selected heart patients enrolled
in clinical trials [9,13,14], patients with known reduced
LVEF [13,14], and patients with chronic heart failure
[11,17]. Only two previous studies included unselected
MI patients, of which one observed an association
between LVEF measured at the time of the MI and later
HRQoL [10,16]. Better understanding of the relationship
between cardiac function and quality of life might con-
tribute to tailor treatment that would maintain or
improve the patients' daily functioning. Evidently, more
research on this subject is needed.
Accordingly, our aim was to assess the relationship
between LVEF measured during hospitalization for acute
MI and HRQoL 2.5 years later in an unselected MI patient
population, using both a generic and a disease-specific
HRQoL measure.
Methods
Study design and sample
We established a cohort of hospitalized patients with a
discharge diagnosis of acute MI, defined as codes I21 and
I22 in ICD-10 (The International Statistical Classification
of Diseases and Related Health Problems, tenth revision)
[18]. We wanted our cohort to be representative of Nor-
wegian patients with MI, and hence recruited them from
teaching and non-teaching hospitals in different regions
of Norway. We included a total of 754 consecutive
patients who were discharged alive from 15 hospitals dur-
ing a 3-month period between August 1, 1999, and Janu-
ary 31, 2000. Before discharge, LVEF was measured in 406
(54%) patients. The patient population is described in
Figure 1.
In 2002, we mailed a questionnaire to patients who were
still alive according to hospital information systems and
the National Population Register of Statistics Norway. The
questionnaires were mailed from the hospital of dis-
Flow chart of study population Figure 1
Flow chart of study population. Study population stratified on patients with and without their left ventricular ejection frac-
tion measured
348 Left ventricular 
ejection fraction 
not measured  
119   Died    
2   Lost to follow up
6   Excluded
221 Sent 
questionnaire  
754 Consecutive patients 
discharged alive 
from 15 hospitals
406 Left ventricular 
ejection fraction 
measured  
72   Died    
6   Lost to follow up
1   Excluded
327 Sent 
questionnaire  
256 Respondents 152 Respondents  
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charge, along with a cover letter signed by the head of the
hospital's cardiology unit. After 4 weeks, we sent a
reminder to non-respondents.
At the time of the survey, 191 of the 754 patients had died,
8 had an unknown address, and 7 were excluded for mis-
cellaneous reasons. Hence, we mailed the questionnaire
to the remaining 548 patients of whom 408 (74%)
returned completed questionnaires. A total of 256 of the
408 respondents (63%) had data on LVEF (Figure 1). The
mean time from the index MI to questionnaire response
was 2.5 (SD = 0.2) years, range 2.1–3.1 years.
Review of medical records
Baseline characteristics were abstracted from the patients'
medical records and included previous medical history,
presenting features, in-hospital treatment, and medica-
tion at discharge. Cardiovascular morbidities from before
the index MI were categorized as previous MI, hyperten-
sion, angina pectoris, heart failure, peripheral vascular
disease, or stroke. The diagnoses were based on either pre-
vious ICD-codes or explicit statements in the medical
record. The major indications for each cardiovascular drug
prescribed at discharge were classified as secondary pre-
vention, hypertension, angina pectoris, heart failure, or
other. More details about sampling and collection of data
from the patients' medical records are available elsewhere
[18].
Measurement of left ventricular ejection fraction
We measured LVEF by one of two methods: Multiple
gated-acquisition radionuclide ventriculography (MUGA)
in 129 (51%) patients and echocardiography in 127
(49%) patients. MUGA is a reliable reference method, and
the widely used echocardiographic method correlates
fairly well with radionuclide imaging [19,20]. LVEF >50%
is considered to indicate normal left ventricular function,
while LVEF <40% indicates reduced function. According
to this classification we categorized LVEF as normal (LVEF
>50%), intermediate (40–50%) or reduced (<40%).
Questionnaire
The questionnaire focused on HRQoL, using the EQ-5D
Index, the EQ-5D Visual Analogue Scale (EQ-VAS), and
the Kansas City Cardiomyopathy Questionnaire (KCCQ).
In addition, we asked about subsequent cardiac events
and revascularization procedures after hospital discharge
for the index MI.
The KCCQ is a self-administered 23-item questionnaire
designed for measuring HRQoL in patients with chronic
heart failure. It comprises six scales: Symptoms, Symptom
stability, Physical limitation, Social limitation, Self-effi-
cacy and Quality of life [21]. Four of the scales, Symp-
toms, Physical limitation, Social limitations and Quality
of life, are aggregated to an overall score, the KCCQ clini-
cal summary score [21]. Each item is scored on a 5 to 7-
point Likert scale [22]. Each scale score is calculated as the
mean of its item scores and transformed to a 0–100 scale,
with higher score indicating higher level of functioning.
The KCCQ has been translated into Norwegian, and its
psychometric properties have been documented in post
MI patients [23]. Change in KCCQ score of 5, 10, and 15
points correspond with small, moderate, and large clinical
change respectively [24].
The EQ-5D is a self-administered HRQoL instrument with
5 items: Mobility, Self-care, Usual activities, Pain/discom-
fort, and Anxiety/depression. Each item is scored on a 3-
point Likert scale: no problems (score of 1), moderate
problems (2), and extreme problems (3). Responses to
these items can be converted to a utility score, the EQ-5D
Index, by applying an algorithm derived from time trade-
off valuations of health status obtained from the general
population [25]. A score of 1.0 represents perfect health
and 0 represents dead. For the EQ-5D Index negative util-
ities are possible, representing states perceived to be worse
than dead. We used a UK time trade-off tariff [26]. The
EQ-5D Index has been used and documented in post MI
patients [27-29]. In addition to the QE-5D Index the EQ-
5D questionnaire include the EQ-VAS, a visual analogue
scale ranging current overall health by one single number
on a scale from 0 (worst imaginable health state) to 100
(best imaginable health state) [28]. The EQ-VAS has doc-
umented acceptable reliability and validity in patients
with CAD [29-31].
Statistical analysis
We present descriptive statistics with means and SDs, or
proportions. For group comparisons, we used the t-test,
analysis of variance, Kruskal-Wallis test for three inde-
pendent groups, Wilcoxon rank-sum test, or chi-square
test where appropriate.
We used multiple linear regression analysis to identify
determinants for KCCQ clinical summary score, EQ-5D
Index, and EQ-VAS at a mean of 2.5 years after MI. To
reduce problems with multicollinearity, we checked pair-
wise Pearson correlations (r) between independent varia-
bles. However, none of the pairwise correlations had r >
0.70. Variables with p < 0.25 in bivariable linear regres-
sion analysis were included in multivariable modeling. In
the multivariable models, we first included age at admis-
sion, sex, length of education in years, and LVEF in the
models, and then added the other potential independent
determinant variables in a forward stepwise fashion. In
addition to age, sex, education, and LVEF, we retained all
independent variables with p < 0.05 in multivavariable
linear regression in the final model. The final models were
checked for interactions.BMC Cardiovascular Disorders 2008, 8:28 http://www.biomedcentral.com/1471-2261/8/28
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The coefficient of determination (R-square) is a measure
of explained variance in regression analysis. To determine
the marginal contribution of LVEF to R-square, in KCCQ
clinical summary score, EQ-5D Index score, and EQ-VAS,
we compared the R-square in the final models adjusted for
degrees of freedom, with R-square in the final models
without LVEF.
We used a 5% significance level with two-sided tests.
Standard statistical software was used for all analyses
(SPSS version 12.0, SPSS, Chicago, IL). The Regional
Committee for Medical Research Ethics and the Norwe-
gian Data Inspectorate approved the study.
Demographics
Respondents (n = 408) were younger than non-respond-
ents (n = 140), comprised a higher proportion of males,
had less cardiovascular morbidity at admission, and fewer
cardiovascular indications for medication at discharge.
Respondents and non-respondents did not differ in the
proportion of patients with ST-segment elevation at
admission, Q-wave infarction, or localization of the index
MI. Respondents who had their LVEF measured (n = 256)
had higher LVEF than non-respondents who had their
LVEF measured (n = 71) (normal, intermediate, reduced:
65%, 22%, 13% vs. 51%, 27%, 23%, p = 0.02). A more
extensive comparison of respondents and non-respond-
ents has been presented elsewhere [23].
Results
Respondents who had their LVEF measured (n = 256) dur-
ing hospitalization for the index MI were younger than
respondents who had not (n = 152), had less cardiovascu-
lar morbidity at admission, and a higher proportion were
smokers. Further, a larger proportion of respondents who
had their LVEF measured had ST-segment elevation MI,
underwent acute revascularisation, and developed Q-
wave MI, and a lower proportion had medication for
angina pectoris at discharge (Table 1).
Among respondents who had their LVEF measured, those
with reduced LVEF were older and had increased preva-
lence of heart failure at admission. There was an increased
prevalence of previous MI, anterior wall infarction, and
use of medication on the indication heart failure with fall-
ing LVEF. Further a smaller proportion of respondents
with reduced LVEF underwent acute revascularization or
had subsequent percutaneous coronary intervention
(Table 1).
Health-related quality of life
The mean score for all patients with LVEF measured was
80 for the KCCQ clinical summary scale, 0.80 for the EQ-
5D Index, and 69 for the EQ-VAS. HRQoL scores differed
between patients with different levels of LVEF both for the
KCCQ clinical summary score (p  < 0.001) the EQ-5D
Index (p = 0.005), and the EQ-VAS (p = 0.001) (Table 2).
In multivariable linear regression analysis, age ≥ 70 years,
a history of chronic obstructive pulmonary disease
(COPD), subsequent MI, and intermediate or reduced
LVEF measured during hospitalization were all independ-
ent determinants of lower KCCQ clinical summary score
2.5 years after the index MI (Table 3). Female sex, medica-
tion for angina pectoris at discharge, and intermediate
LVEF were independent determinants a lower EQ-5D
Index score, while a history of peripheral vascular disease
was associated with a higher EQ-5D Index score (Table 3).
Age 70 ≥ years, a history of COPD, and reduced LVEF were
independent determinants of lower EQ-VAS score (Table
3).
In the final multivariable models, R-square was 0.16 for
both KCCQ clinical summary score and EQ-5D Index,
and 0.10 for the EQ-VAS (Table 3). When excluding LVEF
in the final models, R-square was 0.09, 0.12, and 0.06
respectively, indicating that LVEF accounted for 25% to
44% of the variation explained by the final multivariable
models.
One hospital measured LVEF routinely in all MI patients,
using MUGA (n = 101). When applying our final multi-
variable models in this subset of patients, the relationship
between LVEF and HRQoL was essentially the same as in
all patients with measured LVEF. In this subset, using
KCCQ clinical summary score as the dependent variable,
the unstandardized regression coefficient (B) and 95%
confidence interval (CI) for patients with intermediate
LVEF and reduced LVEF were -10.4 (-21.0 to 0.3) (p =
0.06) and -13.6 (-26.9 to -0.4) (p = 0.04) respectively.
With EQ-5D Index as dependent variable B and 95% CI
were -0.13 (-0.25 to -0.02) (p = 0.02) and -0.02 (-0.16 to
0.12) (p = 0.7).
Discussion
In this study LVEF measured during hospitalization for
the index MI was a determinant of HRQoL 2.5 years later,
with poorer HRQoL in patients with reduced LVEF. This
relationship persisted after adjusting for comorbidities,
sociodemographic variables, and variables related to the
index MI. The summary score of the condition-specific
KCCQ questionnaire, which has been validated in an ear-
lier study [23], and the EQ-VAS showed a trend of falling
scores with falling LVEF, while the EQ-5D Index only cap-
tured a difference between patients with normal and inter-
mediate LVEF. A difference in score for the KCCQ clinical
summary score between patients with normal LVEF and
intermediate or reduced LVEF of 10 and17 points respec-
tively, indicates a moderate to large clinical difference
between the groups of patients with different LVEF [24].BMC Cardiovascular Disorders 2008, 8:28 http://www.biomedcentral.com/1471-2261/8/28
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The observed falling HRQoL scores with falling LVEF both
for KCCQ clinical summary score and EQ-VAS indicate
that the level of systolic heart function is a determinant for
HRQoL. However, some influence from the mere fact that
an MI has occurred cannot be ruled out since also patients
with normal LVEF tend to have reduced EQ-5D scores
compared to US norms [32]. If so, it is possible that other
cardiac pathophysiological mechanisms or psychological
mechanisms are involved. An understanding of the way
LVEF may influence HRQoL can be provided from a con-
ceptual model outlined by Wilson and Cleary [33]. In
their model biological and physiological variables influ-
ence symptoms, that is, patients with reduced LVEF may
experience symptoms such as fatigue, dyspnoea, and sleep
disturbances. These symptoms can in turn affect the
patients' functional status, general health, and overall
quality of life. The impact on individual patients is further
modified by psychological and socioeconomic variables
[33]. In our study the level of LVEF immediately after the
index MI had a statistically significant impact on later
HRQoL and in accordance with the usual interpretation of
the KCCQ the clinical importance was moderate to large
Table 1: Possible determinant variables
All respondents LVEF value
LVEF measured LVEF not measured p Normal (>50%) Intermediate (40 – 50%) Reduced (<40%) p
n 256 152 167 56 33
Time since index MI, years 2.5 (0.2) 2.6 (0.2) <0.001 2.5 (0.2) 2.6 (0.2) 2.5 (0.2) 0.046
Sex (% women) 29 29 1.0 29 30 27 1.0
Age, years 64 (12) 68 (12) 0.002 62 (12) 68 (11) 68 (13) 0.001
Education, years, range 7–
21
10 (3) 10 (4) 0.9 11 (3) 10 (3) 10 (3) 0.3
Smoker at admission 49a 39b 0.07 51c 48d 45e 0.8
Comorbidities before the index 
MI
Diabetes mellitus 10 6 0.3 8 11 15 0.5
Chronic obstructive 
pulmonary disease
8 7 0.7 6 13 6 0.2
Hypertension 29 35 0.2 30 29 24 0.8
Previous MI 17 24 0.08 11 24 36 0.001
Angina pectoris 22 30 0.08 20 22 33 0.2
Peripheral vascular disease 4 9 0.08 2 7 9 0.1
Stroke 5 6 0.5 3 7 12 0.07
Heart failure 2 8 0.009 1 2 9 0.02
Index MI, characteristics
ST-segment elevation 59 35 <0.001 58 70 46 0.07
Localization 0.1 <0.001
Anterior wall 44 30 34 57 70
Inferior wall 41 38 51 27 12
Unknown 16 24 15 16 18
Q-wave 48 33 0.004 47 48 52 0.9
In-hospital treatment
Revascularization 49 22 <0.001 48 63 33 0.02
Indication for medication at 
discharge
Secondary prevention 99 98 0.7 99 100 97 0.4
Hypertension 11 12 0.8 14 5 6 0.1
Angina pectoris 18 35 <0.001 19 18 12 0.6
Heart failure 19 22 0.4 7 29 61 <0.001
Subsequent events
New MI 5 7 0.5 5 5 3 0.8
Percutaneous coronary 
intervention
15 11 0.3 20 5 6 0.008
Coronary artery bypass 
graft surgery
11 13 0.7 12 7 15 0.5
Background variables, characteristics of the index myocardial infarction, treatment and subsequent events according to whether left ventricular 
ejection fraction (LVEF) was measured or not and in patients with normal (>50%), intermediate (40–50%), and reduced (<40%) LVEF. Numbers 
represent mean (SD) or percent.
a n = 227; b n = 137; c n = 150; d n = 48; e n = 29; MI, Myocardial InfarctionBMC Cardiovascular Disorders 2008, 8:28 http://www.biomedcentral.com/1471-2261/8/28
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[24]. However, the observed absolute change in R-square
was small indicating that the amount of variation in
HRQoL scores explained by LVEF was moderate. A mod-
erate amount of variation in HRQoL score explained by a
single clinical variable can be expected if Wilson and
Cleary's model is valid, as other interrelated variables
intervene between pathophysiology of the heart and qual-
ity of life [33].
Three previous studies have observed an association
between LVEF and HRQoL in patients with CAD [8-10].
However, two of these studies reported on patients not
comparable to those in the present study. One reported
on patients admitted to hospital with acute chest pain,
thus including patients with acute MI, unstable angina,
and chest pain of other reasons [8]. The second study pre-
sented results from patients enrolled in a clinical trial of
thrombolysis, thus representing a highly selected group of
MI patients [9]. In the third study Ecochard et al. showed
that LVEF < 46% measured by ventricular angiography
within a month after the index MI was associated with
reduced function on the Physical mobility dimension of
the Nottingham Health Profile (NHP) assessed at one
year [10]. However, they did not observe any association
between LVEF and the five other dimensions of the NHP
(Energy level, Sleep, Pain, Emotional reactions, and Social
isolation). By contrast, we found a relationship between
LVEF and composite HRQoL scales covering physical,
emotional, and social aspects of the HRQoL concept. Fur-
thermore, we observed falling HRQoL scale scores with
falling LVEF for the KCCQ clinical summary score and the
EQ-VAS. Ecochard et al. did not find a similar fall by use
of NHP, neither did we by use of the EQ-5D Index [10].
The dissimilarities might be due to the fact that both NHP
and EQ-5D Index are generic instruments and thus sup-
posed to be less sensitive to smaller changes in health sta-
tus and disease severity than the disease-specific KCCQ
[34]. Another reason why reduced LVEF was not inde-
Table 2: Health-related quality of life scores
Left ventricular ejection fraction
Normal (>50%) Intermediate (40–50%) Reduced (<40%)
n 167 54 33
KCCQ clinical summary score 85 (18) 75 (22) 68 (21)
n 160 53 30
EQ-5D Index 0.83 (0.18) 0.72 (0.27) 0.76 (0.14)
n 148 46 26
EQ-VAS 72 (18) 65 (21) 57 (20)
KCCQ clinical summary score, EQ-5D Index score, and EQ-VAS score according to left ventricular ejection fraction, mean (SD)
KCCQ, Kansas City Cardiomyopathy Questionnaire; EQ-VAS, EuroQol Visual Analogue Scale
Table 3: Multivariable linear regression analyses
KCCQ clinical summary score EQ-5D Index EQ-VAS
B (95%CI) p B (95%CI) p B (95%CI) p
n 253 242 219
Sex (0 = male, 1 = female) -3.4 (-8.8 to 2.1) 0.2 -0.10 (-0.16 to -0.04) 0.001 -1.7 (-7.7 to 4,2) 0.6
Age < 70 years = 0, ≥ 70 years = 1 -6.9 (-12.1 to -1.6) 0.01 -0.03 (-0.09 to 0.03) 0.3 -6.4 (-12.0 to -0,7) 0.03
Education, years (range 7–21) 0.5 (-0.3 to 1.2) 0.2 -0.00 (-0.01 to 0.01) 0.5 -0.09 (-0.9 to 0.7) 0.8
Left ventricular ejection fraction
>50%
40–50% -6.9 (-13.0 to -0.9) 0.02 -0.10 (-0.17 to -0.04) 0.001 -4.3 (-10.7 to 2.1) 0.2
<40% -15.4 (-22.6 to -8.3) <0.001 -0.07 (-0.14 to -0.01) 0.08 -13.5 (-21.4 to -5.6) 0.001
Peripheral vascular disease 0.16 (0.04 to 0.28) 0.01
Chronic obstructive pulmonary disease -12.5 (-21.5 to -3.5) 0.006 -12.1 (-21.5 to -2.8) 0.01
Medication for angina pectoris at discharge -0.11 (-0.17 to -0.04) 0.001
Subsequent myocardial infarction -11.2 (-21.9 to -0.6) 0.04
Total adjusted R-square 0.16 0.16 0.10
Independent determinants of health-related quality of life 2.5 years after myocardial infarction in patients with left ventricular ejection fraction 
measured during index hospitalization.BMC Cardiovascular Disorders 2008, 8:28 http://www.biomedcentral.com/1471-2261/8/28
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pendently associated with lower EQ-5D Index score in our
study was the reduced statistical power due to low number
of respondents with LVEF < 40%.
Studies that did not find an association between LVEF and
later HRQoL also varied with regard to inclusion criteria
and most of them reported on selective groups of patients
and not on unselected acute MI patients as we did [12-16].
One reported on patients 65 years of age or older with
CAD [12], two on clinical trials of post MI patients with
reduced LVEF [13,14], and one on patients with their first
MI receiving thrombolysis [15]. McBurney et al. did not
detect any difference in HRQoL between patients with
LVEF < 40% and patients with normal and sub-normal
LVEF in a patient sample comparable to ours [16]. How-
ever, they used a generic questionnaire, the short form 12
(SF-12) which probably is less sensitive to changes in
health status and disease severity [34].
In our study on MI patients, age ≥ 70 years was associated
with lower KCCQ clinical summary score. This contrasts
with previous results on heart failure patients in which
increased age independently correlated with higher KCCQ
Quality of life scale score [35]. One possible explanation
for this discrepancy is that the KCCQ clinical summery
score, which we used as an HRQoL measure in our study,
is an overall scale including, in addition to the KCCQ
Quality of life scale, scales on symptoms, physical limita-
tions, and social limitations. Another possible explana-
tion is that in our sample of patients with previous MI,
increasing age is associated with more advanced CAD and
age might act as a surrogate for disease severity [36]. This
might not be the case in a sample of patients with heart
failure as the underlying cause in younger patients with
heart failure more commonly is dilated cardiomyopathy
or other cardiomyopathies rather than CAD [35]. We did
not observe an association of age with EQ-5D Index scores
even though EQ-5D Index US norms report a small
decrease in scores with increasing age [32].
We identified sex as an independent determinant of EQ-
5D Index score, but not of KCCQ clinical summary score.
A difference in score between men and women who are
otherwise comparable might be less likely when applying
a disease specific instrument than a generic instrument
which has a broader perspective. Thus, the EQ-5D Index
US norms have reported a small difference between men
and women with poorer score in women [32]. Our obser-
vations are in agreement with these observations.
Our study showed that the presence of COPD was associ-
ated with reduced HRQoL after MI. COPD and CAD share
some causal risk factors, and might to some extent present
with similar symptoms, for example dyspnoea. Therefore,
it is not surprising that patients with COPD who suffer an
MI are at increased risk of impaired HRQoL. Similarly,
medication for angina pectoris was associated with
reduced EQ-5D Index score, and presumably, the reason
for this is the fact that such medication reflects enhanced
disease severity. In our study the presence of peripheral
vascular disease was associated with higher EQ-5D Index
score. However, this finding is based on only 11 patients
with peripheral vascular disease, and therefore should be
interpreted with caution.
Due to the rather long time from the MI to measuring of
HRQoL in our study, the association between LVEF and
HRQoL could have been distorted. Although the patients
reported on intervening major cardiac events, such as new
MI or coronary revascularization procedures, other major
life events, worsening or improvement of illness not
reported in our study, might have had an effect on current
HRQoL. We addressed this issue by entering the time
between the index MI and HRQoL assessment as a varia-
ble in the multivariable analyses. This factor was not,
however, independently associated with HRQoL.
In the context of study limitations the representativeness
of the sample should be discussed. The eligible patients
were representative of survivors of an unselected MI pop-
ulation. Three quarters of the patients responded to the
survey, and LVEF was measured in two thirds of the
respondents, thus we completed our analysis on approxi-
mately half of the eligible patients. This might have
skewed the representativeness. However, results from a
sub-group analysis of patients in one hospital in which all
MI patients had their LVEF measured, were largely in line
with the overall results, indicating that the main results
pertains to unselected MI patients. Another limitation is
the uncertainty of whether the clinicians categorizing the
indications for drugs prescribed at discharge did assign
the most important indication for each drug, as the proto-
col instructed. Cardiovascular drugs may have more than
one indication for use, and we did not assess the reliability
and validity of this classification. However, the classifica-
tion was undertaken by experienced physicians, most of
them cardiologists ensuring the best possible assessment.
Conclusion
LVEF measured during hospitalization for acute MI is an
independent determinant for later HRQoL also after tak-
ing sociodemographic and clinical variables into account.
The magnitude of the difference in HRQoL score between
patients with normal, intermediate, and reduced LVEF
was of clinical importance. As expected, in accordance
with theoretical models, only a moderate amount of the
observed variation in HRQoL score was explained by the
level of LVEF.BMC Cardiovascular Disorders 2008, 8:28 http://www.biomedcentral.com/1471-2261/8/28
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Restoration of myocardial function after an MI is, in addi-
tion to being important for live expectancy, also crucial
for long-term daily functioning after the event.
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